A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

NCT04674189 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2357

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus
Covid19
SARS-CoV-2
Severe Acute Respiratory Syndrome

Interventions

BIOLOGICAL: CVnCoV Vaccine
DRUG: Placebo

Sponsor

CureVac

Collaborators

[object Object]